Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravitreal MK-8748 versus aflibercept for diabetic macular edema
MOH_2026-09-10_017031Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tiespectus in diabetic macular edema (DME) (3 arms), sponsored by Merck & Co. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tiespectus
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2026-09-10_017031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-10_017031.